<DOC>
	<DOCNO>NCT00351416</DOCNO>
	<brief_summary>This research study involve use drug Letrozole , GnRH , NAL-GLU GnRH antagonist . Letrozole drug approve U.S. Food Drug Administration ( FDA ) use breast cancer treatment find block formation estrogen . The NAL-GLU GnRH antagonist drug temporarily block action GnRH . GnRH hormone body make stimulates hormone control function ovary . The purpose study effect administration letrozole woman GnRH deficiency time receive gonadotropin-releasing hormone ( GnRH ) . In addition , administration letrozole NAL-GLU GnRH antagonist healthy woman normal menstrual cycle do evaluate role estrogen control hormone FSH , Follicle Stimulating Hormone , female reproductive cycle . A good understanding FSH control may help development new treatment woman difficulty conceiving .</brief_summary>
	<brief_title>Letrozole Treatment Normal GnRH Deficient Women</brief_title>
	<detailed_description>The negative feedback control FSH crucial precise regulation follicular development female . An important component feedback exert estrogen . Letrozole use block aromatase therefore estradiol production normal GnRH deficient female . These study dissect relative role estradiol inhibin FSH secretion pituitary hypothalamus . The aromatase inhibitor block aromatization androgen estrogens , allow u examine relative contribution estradiol inhibin FSH regulation . Using normal subject GnRH-deficient subject receive replacement GnRH allow u compare effect relative estradiol blockade pituitary ( GnRH deficient subject ) vs pituitary hypothalamus ( normal subject ) , thus determine direct site estradiol action . A thorough understanding estrogen inhibin feedback FSH improve understanding failure follicle development subset patient infertility , polycystic ovary syndrome , FSH level normal follicle fail develop . Study FSH control also help u understand failure negative feedback FSH , result multiple follicular development multiple gestation associate cost risk . Thus , study may afford new therapeutic option conception infertile patient simultaneously provide new method avoid risk multiple gestation .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Kallmann Syndrome</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>LHRH , N-Ac-2-Nal ( 1 ) -4-Cl-Phe ( 2 ) -3-Pal ( 3 ) -Arg ( 5 ) -Glu ( 6 ) -AlaNH2 ( 10 ) -</mesh_term>
	<criteria>Healthy Normal Subjects meet follow criterion : 18 35 year age good general health medication include hormonal drug product least 3 month study regular menstrual cycle every 2535 day ovulation document luteal phase progesterone &gt; 3 ng/ml evidence androgen excess normal TSH , prolactin hemoglobin use doublebarrier contraception , permanent sterilization abstinence cycle study . Negative pregnancy test ( serum ) begin cycle study Normal Liver Function Test GnRH Deficient Subjects meet follow criterion : 18 40 year age good general health gonadal replacement least 1 month study GnRH deficiency ( idiopathic hypogonadotropic hypogonadism Kallmann 's Syndrome , secondary hypothalamic amenorrhea , acquire hypogonadotropic hypogonadism ) normal TSH , prolactin hemoglobin use doublebarrier contraception abstinence cycle Letrozole administration Negative pregnancy test ( serum ) begin cycle study Normal Liver Function Test History liver and/or kidney disease Substance alcohol abuse Hormone dependent neoplasia include breast cancer Women try become pregnant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>GnRH deficiency</keyword>
	<keyword>GnRH antagonist</keyword>
	<keyword>Letrozole</keyword>
	<keyword>GnRH</keyword>
	<keyword>FSH</keyword>
	<keyword>LH</keyword>
	<keyword>Inhibins</keyword>
</DOC>